PKU Healthcare Corp. (000788.SZ) stated on the investor interaction platform that the company's current focus in the pharmaceutical manufacturing sector is on three main areas: anti-infective, analgesic, and psychiatric drugs, mainly generic drugs. Among them, the anti-infective products include Clindamycin Palmitate Hydrochloride Granules (used for various infectious diseases caused by gram-positive bacteria, such as tonsillitis, acute bronchitis, pneumonia, etc.), Moxifloxacin Hydrochloride Injection (used for respiratory tract infections in adults (≥18 years old) such as acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, uncomplicated skin and skin tissue infections, etc.), and Meropenem for injection (used for infections in adults and children caused by single or multiple bacteria sensitive to meropenem, such as pneumonia (including hospital-acquired pneumonia), urinary tract infections, etc.).